Assays

#Assays #Biotherapeutics #Drug targets #Mass spectrometry / NMR #Webinar

Webinar: How to tackle the challenges of peptide and protein quantification

The importance of biotherapeutics as a class of drugs continues to increase. Indeed, their low toxicity and high specificity justify their investigation as drug candidates. Yet, quantification studies of biotherapies in complex biological matrices can be very challenging. In particular, high background noise and interferences due to endogenous proteins… Read More

#News

#Assays #Drug discovery #High throughput screening #Technology

Case study outlines how to create more therapeutic opportunity

Pairing the right small molecule library with innovative high-throughput screening creates more therapeutic opportunity, this SAMDI Tech case study shows.  Finding an encouraging drug lead that selectively engages a target of interest is the result of several matches that lead to successful drug discovery programmes, including: … Read More

#News

Scientists in medical research lab
#Assays #Live cell analysis

New edition of Live-Cell Analysis Handbook available 

Sartorius has released the fifth edition of its Live-Cell Analysis Handbook, a reference guide for live-cell analysis technologies, focusing on the complete suite of Incucyte live-cell assays and reagents.   The live-cell applications covered in the Live-Cell Analysis Handbook include cell culture quality control assays and kinetic assays for cell health and… Read More

#News

#Assays #Cell and gene therapy #Drug development #Immunology

Collaboration agreement for ImmunoBiopsy platform 

Orgenesis has entered into a collaboration agreement with Savicell Diagnostics to deploy Savicell’s patented ImmunoBiopsy immunometabolism platform. The aim is to develop and validate diagnostic kits for enhanced quality control (QC) and monitoring purposes to be used by Orgenesis in manufacturing and processing of its cell and gene therapies. New assays will be developed to enhance the potency of cell and gene therapies… Read More

#Business & Investment #News

#Assays #Biosciences #Protein chemistry / Proteomics

Protein-protein Interactions Using NanoBRET Technology

In this video, Dr Gary Allenby, CEO Aurelia Bioscience, describes a scientific poster on ‘Protein-protein Interactions Using NanoBRET Technology’. Historically, only solution-based assays were used to screen compounds in PPI, but a more physiological approach is to examine the interaction in living cells. However, there are very few… Read More

#News #Trending News #Videos

#AI / data analytics / healthtech / informatics #Assays #Covid-19 #Drug development

Human studies begin on AI Covid-19 treatment with up to 97% effectiveness

Skymount Medical and Louisiana State University (LSU) have commenced human studies on a unique combination of therapies for Covid-19 patients, known as SM-19. In vitro and in vivo assays conducted by the IIT Research Institute (IITRI) in Chicago showed significant efficacy in reducing viral load of the SARS-Cov-2 virus. The… Read More

#News #Trending News

#Assays #Biotherapeutics #C elegans #Drug development #Drug discovery #Therapeutics #Viosciences

Unlocking the microbiome as a target for drug discovery using C. elegans

David Weinkove, CEO Magnitude Biosciences, examines the untapped microbiome and its potential into helping unlock new therapies. Why the microbiome? The human microbiome is an important emerging field for drug discovery that harbours an array of life-changing medicines for patients. Whilst it is increasingly acknowledged that the human microbiome holds… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Assays #Biotechnology #Life sciences #Therapeutics

PerkinElmer expands KRAS oncology drug discovery assays

PerkinElmer has released four new ready-to-use AlphaLISA KRAS kits, designed to help scientists better understand complex KRAS protein structures and mutations so they can more easily, quickly, and precisely identify potential new therapeutic candidates for a wide range of prevalent cancers. Researchers will now be able to choose between PerkinElmer’s… Read More

#News

#Assay development optimisation & technology #Assays #Drug discovery #Drug toxicity #In vitro #Podcast

Podcast: Paving the way for optimum drug discovery

This is the latest episode of the free DDW podcast, “Paving the way for optimum drug discovery”. It covers two narrated articles written for Volume 22, Issue 1 – Winter 2020/21 of DDW and they are read aloud by Megan Thomas. These articles are titled: “In vitro models for assessing… Read More

#News

#Assays #Drug delivery #Drug discovery #In vitro

Gentronix acquires Big Blue transgenic mutation assay models

UK-based Contract Research Organisation (CRO) Gentronix is set to expand its genetic toxicology capabilities and accelerate its growth following acquisition of the Big Blue transgenic mutation assay models. The acquisition ensures the continuing market provision of the Big Blue transgenic assays for companies requiring mutagenicity assessment under the OECD 488… Read More

#News

#Assays #Clinical trials #Drug toxicity #Preclinical development #Toxicology

Driving the success of predictability in preclinical development 

The development of predictive preclinical assays is key to success in drug development. It is therefore critical to carefully construct biomarker studies using the most appropriate assays that better represent the complex physiology of disease for the reliable assessment of safety, efficacy, and dose predictions. To explore this topic further, Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases,… Read More

#Editor's Choice #News

#Antibodies #Assays #Pharmaceuticals #Small molecules

Synthesising new solutions for small molecule antibodies

Toni Rogers and David Bunka, Aptamer Group discuss how newer antibody alternative technologies are demonstrating significant developments, offering novel solutions to improve success, decrease project timelines and produce innovative low-cost assays to small molecule targets across many sectors. Small molecules are ubiquitous in our environment, from toxins and heavy metals… Read More

#Editor's Choice #Exclusive Content #News

#Assays #Biologics / Biotechnology #Covid-19 #Data

GSK and Vir Biotechnology request for EUA for COVID-19 treatment

GlaxoSmithKline (GSK) and Vir Biotechnology have announced the submission of an application to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorisation (EUA) for VIR-7831 (GSK4182136), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents (aged 12 years and older weighing at least 40… Read More

#Covid-19 #News

#Assays #Automation / robotics #Flow Cytometry

How to boost productivity with high-throughput flow cytometry automation

High-throughput flow cytometry technologies have revolutionised drug screening, says Bio-Rad. This application note explains how you can take throughput and reproducibility to the next level using the ZE5 Cell Analyzer. In the current environment, with increased pressures on drug companies, Bio-Rad believes using effective automation is critical. This application note… Read More

#News

#Assays #Biologics / Biotechnology #Drug discovery

Axol Bioscience: multi-electrode array screening for human iPSC-derived cells 

Axol Bioscience, a biotechnology company specialising in the use of stem cell technology to manufacture disease-relevant cell-based assay systems to the drug discovery industry, has introduced multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells. The new services have been developed to support pre-clinical research by optimising hiPSC-derived… Read More

#News